RESUMEN

Using conventional Sanger sequencing as a reference standard, we compared the sensitivity, specificity, and capacity of the Illumina GA II platform for the detection of TP53, BRCA1, and BRCA2 mutations in established tumor cell lines and DNA from patients with germline mutations. A total of 656 coding variants were identified in four cell lines and 65 patient DNAs. All of the known pathogenic mutations (including point mutations and insertions/deletions of up to 16 nucleotides) were identified, using a combination of the Illumina data analysis pipeline with custom and commercial sequence alignment software. In our configuration, clonal sequencing outperforms current diagnostic methods, providing a reduction in analysis times and in reagent costs compared with conventional sequencing. These improvements open the possibility of BRCA1/2 testing for a wider spectrum of at-risk women, and will allow the genetic classification of tumors prior to the use of novel PARP inhibitors to treat BRCA-deficient breast cancers.

Asunto(s)

Neoplasias de la Mama/diagnóstico , Neoplasias de la Mama/genética , Pruebas Genéticas/métodos , Análisis de Secuencia de ADN/métodos , Proteína BRCA1/genética , Proteína BRCA2/genética , Secuencia de Bases , Células Clonales/metabolismo , Células Clonales/patología , ADN Intergénico/genética , Femenino , Humanos , Datos de Secuencia Molecular , Mutación/genética , Reacción en Cadena de la Polimerasa , Reproducibilidad de los Resultados , Alineación de Secuencia